On 2026-09-09, Leerink initiated coverage of TEVA with a Outperform rating.
Leerink 于 2026-09-09 首次覆盖 TEVA，初始评级为 跑赢大市（Outperform）。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
Mignone Roberto sells $14.4M of TEVAMignone Roberto 内部减持 梯瓦制药公司 (TEVA) $14.4M
Insider Sale · September 22, 2026内部人减持 · 2026/9/22
TEVA PHARMACEUTICAL INDUSTRIES LTD details a $4.90B ADS offering in 424B5 prospectus梯瓦制药公司 (TEVA) 提交 424B5 招股文件，拟发行 $4.90B 的美国存托股
SEC Material Disclosure · September 11, 2026SEC 重大披露 · 2026/9/11
TEVA financing pricing: Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior NotesTeva Pharmaceutical Industries Limited（TEVA）完成融资定价，规模 $4.9B
Material Company Event · September 10, 2026公司公告 · 2026/9/10
